Global & Regional Health Technology Assessment最新文献_第10页

Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain. 医院药房和社区药房之间的护理连续性，并避免成本:西班牙在2019冠状病毒病期间的试点经验

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2021-01-01 DOI: 10.33393/grhta.2021.2215

Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo

{"title":"Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain.","authors":"Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo","doi":"10.33393/grhta.2021.2215","DOIUrl":"https://doi.org/10.33393/grhta.2021.2215","url":null,"abstract":"Introduction: In March 2020, due to the pandemic caused by COVID-19, a pilot experience of pharmaceutical continuity of care received by hospital outpatients was launched in Cantabria, a Spanish autonomous community. Thanks to this experience, the medication was dispensed by the hospital pharmacy through the community pharmacy of the patient's choice. Our objective was to estimate the costs avoided by this practice during the months of April and May 2020.Methods: The analysis of the economic impact was carried out in terms of saved costs, from the hospital and from the social perspective. Savings associated with the avoided home delivery of medication and avoided labor productivity losses were calculated, as well as the time associated with avoided trips in monetary terms.Results: A total of 2,249 hospital-dispensed drugs were delivered through the community pharmacy in the analyzed period, with an average of 57.7 daily deliveries. The experience, which involved one hospital and 262 pharmacies of Cantabria, saved patients 93,305 km in trips to the hospital, associated with an average time saving of 1,374 hours. In terms of costs, the hospital saved on shipments by courier, estimated at €30,205, since it was the community pharmacy and the distribution warehouses that delivered the drugs. From a social perspective, this initiative saved €23,309 due to the trips (€8,907) and productivity losses (€14,402) that were avoided.Conclusions: This exceptional situation may be a good opportunity to improve the coordination between hospital pharmacies and community pharmacies in Spain, not only during the pandemic but also in the post-COVID-19 era.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"8 ","pages":"8-13"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/04/grhta-8-8.PMC9616201.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10869817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Costo per responder di upadacitinib e abatacept nel trattamento dell’artrite reumatoide da moderata a grave in Italia. 在意大利，upadacitinib和abatacept治疗风湿性关节炎中度到严重关节炎的费用。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2021-01-01 DOI: 10.33393/grhta.2021.2267

Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

{"title":"Costo per responder di upadacitinib e abatacept nel trattamento dell’artrite reumatoide da moderata a grave in Italia.","authors":"Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi","doi":"10.33393/grhta.2021.2267","DOIUrl":"https://doi.org/10.33393/grhta.2021.2267","url":null,"abstract":"Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy. Methods: The clinical efficacy was assessed based on SELECT-CHOICE study results. The clinical efficacy of upadacitinib and abatacept (iv or sc) was measured by Clinical Remission (CR), Low Disease Activity (LDA) and American College of Rheumatology response (ACR20, 50 and 70). The treatment cost was based on the number of administrations dispensed at 12 or 24 weeks. The cost per responder was adopted as a cost-effectiveness indicator. Results: Independent of the clinical efficacy measure used and the duration of treatment considered, the cost per responder was consistently lower for upadacitinib compared to abatacept (iv or sc) across all clinical measures. For example, considering the CR at 24 weeks, the cost per responder for upadacitinib was € 9,417 compared to € 17,817 for abatacept sc or to € 23,110 for abatacept iv. The differences in the cost per responder between upadacitinib and abatacept (iv or sc) increased when higher ACR response levels were considered. Conclusions: These results suggested that upadacitinib is a cost-effectiveness option compared to abatacept (iv or sc) from the perspective of the Italian National Health Service in patients with moderate-to-severe Rheumatoid Arthritis in Italy.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"8 ","pages":"69-79"},"PeriodicalIF":0.5,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/e1/grhta-8-69.PMC9616195.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10869818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Author's reply to comments on "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain". 提交人对“医院药房和社区药房之间护理的连续性和成本的避免:西班牙COVID-19时期的试点经验”评论的回复。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2021-01-01 DOI: 10.33393/grhta.2021.2272

Néboa Zozaya

引用次数: 3

Towards standardization of economic evaluation research in the youth psychosocial care sector: A broad consultation in the Netherlands. 实现青年社会心理关怀领域经济评估研究的标准化：荷兰的广泛咨询。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2020-12-14 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.2143

Silvia M A A Evers, Carmen D Dirksen

{"title":"Towards standardization of economic evaluation research in the youth psychosocial care sector: A broad consultation in the Netherlands.","authors":"Silvia M A A Evers, Carmen D Dirksen","doi":"10.33393/grhta.2020.2143","DOIUrl":"10.33393/grhta.2020.2143","url":null,"abstract":"Introduction: Stakeholders are increasingly interested in the societal impact of psychosocial interventions in the youth sector, in terms of costs and quality of life, as well as in outcomes research. The aim of this broad consultation was to reach consensus regarding the steps to be undertaken to set a research agenda for the Netherlands Organisation for Health Research and Development (ZonMw) programme.Methods: The broad consultation consisted of an eight-step procedure, including the conceptualization of a consultation document consisting of a scoping review of (mainly) international opinion/methodological literature and an inventory of existing Dutch guidelines and manuals for economic evaluation, a written consultation procedure among a broad range of stakeholders, and a consultation meeting with these stakeholders.Results: In total 21 documents were included in the scoping review. A total of 24 stakeholders participated in the written consultation procedure and 14 stakeholders during the consultation meeting. The methodological issues and challenges, which were ranked in the top 5 by the stakeholders, are (i) outcome measurement, (ii) outcome identification, (iii) cost valuation, (iv) outcome valuation, and (v) time horizon/analytical approach. The existing guidelines and manuals provided guidance for some, but not all, issues and challenges.Discussion and conclusion: This broad consultation has contributed to a research agenda for the ZonMw programme, which will in the long run lead to the standardization of economic evaluations in this sector in the Netherlands and methodological improvement of economic evaluations in the Dutch youth sector.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"7 ","pages":"117-123"},"PeriodicalIF":0.4,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/fb/grhta-7-117.PMC9677588.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9083786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illness. 改善重症精神病患者心脏代谢健康的生活方式干预的成本效益和预算影响。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2020-12-14 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.2027

Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert A Schoevers, Eva Corpeleijn, Talitha L Feenstra, A D I Thea van Asselt

{"title":"Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illness.","authors":"Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert A Schoevers, Eva Corpeleijn, Talitha L Feenstra, A D I Thea van Asselt","doi":"10.33393/grhta.2020.2027","DOIUrl":"10.33393/grhta.2020.2027","url":null,"abstract":"Introduction: This study assessed the cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in severe mentally ill (SMI) patients in the LION trial.Methods: Patients (n = 244) were randomized to receive either care-as-usual or a lifestyle intervention in which mental health nurses coached patients in changing their lifestyle by using a web tool. Costs and quality of life were assessed at baseline and at 6 and 12 months. Incremental costs per centimeter waist circumference (WC) lost and per Quality-Adjusted Life Year (QALY) gained were assessed. Budget impact was estimated based on three intervention-uptake scenarios using a societal and a third-party payer perspective.Results: Costs and reduction in WC were higher in the intervention (n = 114) than in the control (n = 94) group after 12 months, although not statistically significant, resulting in €1,370 per cm WC lost. QALYs did not differ between the groups, resulting in a low probability of the intervention being cost-effective in cost/QALY gained. The budget impact analysis showed that for a reasonable participation of 43%, total costs were around €81 million over 5 years, or on average €16 million annually (societal perspective).Conclusions: The intervention is not cost-effective at 12 months and the budget impact over 5 years is substantial. Possibly, 12 months was too short to implement the intervention, improve cardiometabolic health, and reduce care costs. Therefore, the incentive for this intervention cannot be found in short-term financial advantages. However, there may be benefits associated with lifestyle interventions in the long term that remain unclear.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"7 ","pages":"131-138"},"PeriodicalIF":0.4,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/1a/grhta-7-131.PMC9677596.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10870302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Il burden economico dell’inappropriatezza prescrittiva nella gestione dell’osteoartrite in Italia. 意大利骨关节炎治疗中处方不当造成的经济负担。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2020-12-10 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.2130

Michele Basile, Filippo Rumi, Marco Palmeri, Ivano Mattozzi, Lamberto Manzoli, Massimo Mammucari, Sergio Gigliotti, Roberto Bernabei, Americo Cicchetti

引用次数: 0

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still's Disease. 阿那白那治疗斯蒂尔氏病患者的预算影响分析。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2020-09-30 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.2187

Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

引用次数: 0

Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. 西班牙国家卫生系统中银屑病的多学科方法:投资的社会回报研究。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2020-07-17 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.2146

Gregorio Carretero, David Moreno, Almudena González-Domínguez, David Trigos, Albert Ledesma, Esther Sarquella, María Merino, Carles Blanch

{"title":"Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study.","authors":"Gregorio Carretero, David Moreno, Almudena González-Domínguez, David Trigos, Albert Ledesma, Esther Sarquella, María Merino, Carles Blanch","doi":"10.33393/grhta.2020.2146","DOIUrl":"10.33393/grhta.2020.2146","url":null,"abstract":"Introduction: Psoriasis is a chronic disease in which patients feel stigmatization, social rejection, and suffer from low self-esteem. There are still unmet needs that make it necessary to define a new multidisciplinary approach to provide benefits not only to patients and their families but also to the Spanish National Health System (SNHS) and society. The aim was to define a new approach to better address the unmet needs of patients with psoriasis within the SNHS and to measure its impact from a social perspective, that is, in clinical, health care, economic, and social terms.Methods: Multidisciplinary experts identified, agreed on, and selected several health care interventions that were feasible for implementation in the SNHS. This process was carried out in four different areas: diagnosis, mild psoriasis, moderate psoriasis, and severe psoriasis. To estimate investment and social return, the social return on investment (SROI) method was used.Results: The new approach to psoriasis management in the SNHS comprised 18 proposals. The investment needed for the implementation of this new approach would amount to €222.77 million and its return to €1,123.11 million. This would yield a SROI ratio of €5.04 for every euro invested.Conclusion: The new approach to psoriasis management would yield a positive social return. The results will allow optimal strategic planning adapted to each assistance situation, to achieve a comprehensive and multidisciplinary approach.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"7 ","pages":"50-56"},"PeriodicalIF":0.5,"publicationDate":"2020-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/d0/grhta-7-50.PMC9677591.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10279647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Valutazione dell’utilizzo di Floseal®, un agente emostatico topico, in chirurgia cardiotoracica. 评估 Floseal® 这种局部止血剂在心胸外科手术中的应用。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2020-05-20 eCollection Date: 2020-01-01 DOI: 10.33393/grhta.2020.695

Rossella Di Bidino, Luz Irene Urbina, Marco Oradei, Americo Cicchetti

引用次数: 0

L’impatto della cross-copertura di dupilumab sulla spesa a carico del Servizio Sanitario Nazionale. dupilumab的交叉覆盖对国家卫生服务支出的影响。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2020-01-01 DOI: 10.33393/grhta.2020.2139

Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria P Pedone, Walter Canonica

{"title":"L’impatto della cross-copertura di dupilumab sulla spesa a carico del Servizio Sanitario Nazionale.","authors":"Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria P Pedone, Walter Canonica","doi":"10.33393/grhta.2020.2139","DOIUrl":"https://doi.org/10.33393/grhta.2020.2139","url":null,"abstract":"Background and research question: Label extension for treatments and the relevant disease cross-coverage may produce an economic benefit. This paper assesses this benefit for dupilumab in the perspective of the Italian National Health Service. Dupilumab was approved for reimbursement for severe atopic dermatitis (AD), severe and refractory asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The analysis focused on the crowding-out effect of dupilumab on alternative treatments. \u0000Methods: The research relied on a simplified budget impact model. The model was populated by data from published evidence and relied on three alternative scenarios for market penetration (15%-30%-100%). \u0000Results: Avoidable direct health annual costs due to cross-coverage for (i) asthma in patients treated for AD ranged from 0.46 to 3.43 million euros, (ii) asthma in patients treated for CRSwNP ranged from 0.08 to 0.88 million euros, (iii) CRSwNP in patients treated for asthma ranged from 0.41 to 4.05 million euros respectively. The total economic benefit ranges from 0.95 to 8.36 million euros. \u0000Discussion: The research estimated the crowding-out effect of dupilumab on alternative treatments. It did not incorporate avoided/incremental events due to a possible better/worse risk-benefit profile of dupilumab vs alternative treatments and the economic benefit of cross-coverage on lower diseases severity (for example mild asthma). Nonetheless, the analysis relies on the best available evidence for Italy to shed light on a topic which has not been sufficiently investigated, and provides data that will be potentially very important for policy-makers, payers and those who manage new treatments.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"7 ","pages":"33-39"},"PeriodicalIF":0.5,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/ef/grhta-7-33.PMC9677606.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10520544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2